USFDA approves Zydus copy of cholesterol drug Colestid
The Hindu
“The Abbreviated New Drug Application of the company is only the second generic application approved by USFDA for this product,” Zydus said
Zydus Lifesciences has received final approval from the U. S. Food and Drug Administration (USFDA) to market its generic version of cholesterol lowering drug Colestipol Hydrochloride tablets, in the strength of 1mg.
“The Abbreviated New Drug Application (ANDA) of the company is only the second generic application approved by USFDA for this product,” Zydus said. “The approved product, which is a generic version of Colestid, will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad,” it said.
“Colestipol Hydrochloride is a highly complex macro molecule drug substance with little or no systemic absorption. The tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet,” Zydus Lifesciences (formerly known as Cadila Healthcare) said.
“The group now has 330 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04,” it said.
Micron said the transaction is expected to close by the second quarter of 2026, subject to regulatory approvals.
China's economy grew 5% in 2025, fueled by strong exports, despite challenges from Trump tariffs and slowing growth in Q4.
Board meeting to appoint Neville Tata as trustee of Sir Ratan Tata Trust cancelled due to lack of quorum.
Industry leaders urge Budget 2026 to reform crypto tax policies, promoting local investment and enhancing regulatory compliance in India.
India's power distribution utilities reported a ₹2,701 crore profit in FY25, reversing years of losses and improving performance indicators.
India prepares for a strong presence at WEF 2026 in Davos, featuring key ministers and top CEOs engaging with global leaders.
Davos prepares for the 2026 World Economic Forum with unprecedented security measures as global leaders gather amidst planned protests.
Mercedes-Benz India CEO advocates for rationalizing customs duties on luxury cars to boost demand and tax revenue in India.
IDBI Bank's Q3 net profit rises slightly to ₹1,935 crore, with total income and interest income declining.
HDFC Bank Ltd., India’s largest private sector bank, reported 11.5% growth in net profit for the quarter ended 31 December 2026 at ₹18,654 crore compared with ₹16,735.5 crore a year ago.
When Union Minister for Road Transport and Highways, Nitin Gadkari, recently spoke about the transformative potential of Vehicle-to-Vehicle (V2V), a technology for autonomous driving in India, he framed it as a critical lever for safer roads, smarter traffic management and future-ready mobility. That vision is already finding concrete expression inside Samsung Electronics-owned HARMAN Automotive’s India operations, which are emerging as a global hub for software-defined and connected vehicle technologies, says Krishna Kumar, Managing Director and Automotive Head, HARMAN India.
Instituting production-linked incentive (PLI) schemes to curtail import dependency on critical components in the longer-term, and rationalising import duties for support in the short term, forms the core of the wind energy producers’ wish list in the upcoming Union Budget.
ICICI Bank Ltd., the second largest private sector bank, for the third quarter ended 31 December 2025 reported 4% drop in net profit to ₹11,318 crore as compared to ₹ 11,792 crore in the year ago period on account of making additional standard asset provision of ₹1,283 crore during the quarter as per direction of the Reserve Bank of India (RBI).